Patents by Inventor Hugh Smyth

Hugh Smyth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240099967
    Abstract: Provided herein is an inhalable composition of clofazimine. Further provided herein are methods of producing the inhalable clofazimine composition by jet milling. Also provided herein are methods of treating pulmonary diseases by administering the inhalable clofazimine composition.
    Type: Application
    Filed: August 30, 2023
    Publication date: March 28, 2024
    Inventors: Hugh SMYTH, Ashlee BRUNAUGH
  • Patent number: 11911390
    Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: February 27, 2024
    Assignee: Respira Therapeutics, Inc.
    Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
  • Publication number: 20240028790
    Abstract: A forecasting modeling computing system includes a processors and a memory including a set of computer-executable instructions that, when executed by the processor, cause the forecasting modeling computing system to receive design parameters, determine a predicted median particle size, identify a predictive quadratic model, and display a response surface visualization. A computer-implemented method includes receiving design parameters, determining a predicted median particle size, identifying a predictive quadratic model; and display a response surface visualization.
    Type: Application
    Filed: December 22, 2021
    Publication date: January 25, 2024
    Inventors: Tian Wu, Michael Schneider, Ryan Khalaf, Hugh Smyth, Ashlee Brunaugh, Li Ding
  • Patent number: 11806314
    Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: November 7, 2023
    Assignee: Respira Therapeutics, Inc.
    Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
  • Patent number: 11767737
    Abstract: Disclosed herein are compositions and methods for reducing fluid loss in a well bore, methods for wellbore strengthening and increasing the integrity of the borehole of an oil or gas well. Also disclosed are methods for artificially increasing the temperature of a subsurface formation in the wellbore to increase the apparent wellbore strength. The mechanism for accomplishing this revolves around increasing fracture propagation pressure by actively manipulating thermal wellbore stresses.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: September 26, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Eric Van Oort, Besmir B. Hoxha, Ali Karimi Vajargah, Robert O. Williams, III, Hugh Smyth, Silvia Ferrati
  • Publication number: 20230001114
    Abstract: A dry powder inhaler includes a powder storage element configured to hold a powdered medicament and an inlet channel receives, powdered medicament from the powder storage element that is entrained in an airflow. The inlet channel has a first diameter and defines an opening. The inhaler includes a dispersion chamber that receives the airflow and the powdered medicament from the opening. The dispersion chamber has a second diameter. The inhaler includes an actuator housed within the dispersion chamber. The actuator oscillates within the dispersion chamber when exposed to the airflow to deaggregate the powdered medicament entrained by the airflow passing through the dispersion chamber. A ratio between the first diameter and the second diameter is between about 0.40 and 0.60 such that an audible sound is produced as the actuator oscillates. The inhaler includes an outlet channel through which the airflow and powdered medicament exit the inhaler.
    Type: Application
    Filed: September 12, 2022
    Publication date: January 5, 2023
    Applicant: Respira Therapeutics, Inc.
    Inventors: Robert M. Curtis, Dan Deaton, James Hannon, Hugh Smyth, Zhen Xu, Martin Donovan, Aileen Gibbons
  • Patent number: 11491160
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: November 8, 2022
    Assignee: Respira Therapeutics, Inc.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • Patent number: 11491161
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: November 8, 2022
    Assignee: Respira Therapeutics, Inc.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • Publication number: 20220347183
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Application
    Filed: June 29, 2022
    Publication date: November 3, 2022
    Applicant: Respira Therapeutics, Inc.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • Patent number: 11471623
    Abstract: A dry powder inhaler includes a powder storage element configured to hold a powdered medicament and an inlet channel receives powdered medicament from the powder storage element that is entrained in an airflow. The inlet channel has a first diameter and defines an opening. The inhaler includes a dispersion chamber that receives the airflow and the powdered medicament from the opening. The dispersion chamber has a second diameter. The inhaler includes an actuator housed within the dispersion chamber. The actuator oscillates within the dispersion chamber when exposed to the airflow to deaggregate the powdered medicament entrained by the airflow passing through the dispersion chamber. A ratio between the first diameter and the second diameter is between about 0.40 and 0.60 such that an audible sound is produced as the actuator oscillates. The inhaler includes an outlet channel through which the airflow and powdered medicament exit the inhaler.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: October 18, 2022
    Assignee: Respira Therapeutics, Inc.
    Inventors: Robert M. Curtis, Dan Deaton, James Hannon, Hugh Smyth, Zhen Xu, Martin Donovan, Aileen Gibbons
  • Publication number: 20220143034
    Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
    Type: Application
    Filed: January 20, 2022
    Publication date: May 12, 2022
    Applicant: Respira Therapeutics, Inc.
    Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
  • Publication number: 20220079949
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Application
    Filed: November 23, 2021
    Publication date: March 17, 2022
    Applicant: Respira Therapeutics, Inc.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • Publication number: 20220016126
    Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
    Type: Application
    Filed: March 24, 2021
    Publication date: January 20, 2022
    Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
  • Publication number: 20210284688
    Abstract: The present invention relates to a screening method to identify mucus-penetrating compounds. In certain aspects, the present invention relates to mucus-penetrating peptides and constructs comprising an agent, such as a therapeutic agent, imaging agent or diagnostic agent, conjugated to a mucus-penetrating peptide.
    Type: Application
    Filed: July 14, 2017
    Publication date: September 16, 2021
    Inventors: Debadyuti GHOSH, Hugh SMYTH
  • Publication number: 20210205318
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Application
    Filed: January 11, 2021
    Publication date: July 8, 2021
    Inventors: Jeffry WEERS, Alain ROMERO, Hugh SMYTH, Robert CURTIS, Adaani FROST, Zhen XU, Revati SHREENIWAS, Martin DONOVAN
  • Patent number: 11008832
    Abstract: Disclosed herein are compositions and methods for reducing fluid loss in a well bore. Also disclosed herein are methods for wellbore strengthening and increasing the integrity of the borehole of an oil or gas well. In particular, disclosed are methods for artificially increasing the temperature of a subsurface formation in the wellbore to increase the apparent wellbore strength.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: May 18, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Eric Van Oort, Besmir B. Hoxha, Ali Karimi Vajargah, Robert O. Williams, III, Hugh Smyth, Silvia Ferrati
  • Publication number: 20210115760
    Abstract: Disclosed herein arc compositions and methods for reducing fluid loss in a well bore. This invention relates to methods for wellbore strengthening and increasing the integrity of the borehole of an oil or gas well. In particular, the invention relates to methods for artificially increasing the temperature of a subsurface formation in the wellbore to increase the apparent wellbore strength. The mechanism for accomplishing this revolves around increasing fracture propagation pressure by actively manipulating thermal wellbore stresses.
    Type: Application
    Filed: August 28, 2020
    Publication date: April 22, 2021
    Inventors: Eric Van Oort, Besmir B. Hoxha, Ali Karimi Vajargah, Robert O. Williams, III, Hugh Smyth, Silvia Ferrati
  • Patent number: 10967065
    Abstract: In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: April 6, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hugh Smyth, Ju Du
  • Publication number: 20210072231
    Abstract: Devices, systems and methods to directly quantify molecular entities and, compounds, inactive ingredients, compositions or formulations across and into specific layers of biological membranes, such as the skin. Exemplary methods enable the determination of the amount of drug into and across tissues as well as the measurement of the effect of chemicals/compounds on membranes, mainly the skin.
    Type: Application
    Filed: September 9, 2020
    Publication date: March 11, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: Hugh SMYTH, Patricia PEREIRA MARTINS
  • Patent number: 10912778
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 9, 2021
    Assignee: RESPIRA THERAPEUTICS, INC.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan